Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate.

J Thromb Haemost · 2021 · PMC8252511 · PMID 33687782

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.2400

boldest claim

The sentences

borderline significantp = .07so close (0.05 < p ≤ 0.1)

Dabigatran treatment showed a borderline significant reduction of vascular calcification compared with control ( p = .07).

also in 11,409 other papers

showed a trendp = .24not close (p > 0.1)

Short‐term (6 weeks) treatment did not significantly alter plaque size between groups, although warfarin showed a trend toward smaller plaques compared with control and dabigatran treatment ( p = .24 and p = .09 for warfarin vs control and DE, respectively; Figure 1B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.